公开(公告)号：US07601709B2

公开(公告)日：2009-10-13

申请号：US10774047

申请日：2004-02-06

Applicant: Zhenwei Miao ,  Ying Sun ,  Suanne Nakajima ,  Datong Tang ,  Frank Wu ,  Guoyou Xu ,  Yat S. Or ,  Zhe Wang

Inventor： Zhenwei Miao ,  Ying Sun ,  Suanne Nakajima ,  Datong Tang ,  Frank Wu ,  Guoyou Xu ,  Yat S. Or ,  Zhe Wang

IPC: C07D245/00 ,  C07D487/00 ,  A61K31/33 ,  A01N43/00

CPC classification number: C07D487/04 ,  A61K38/12 ,  C07K5/0806 ,  E05F15/73 ,  E05F2015/763

Abstract: The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明涉及式I，II或III的化合物或其药学上可接受的盐，酯或前药：其中W是取代或未取代的杂环体系。 该化合物抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20090149491A1

公开(公告)日：2009-06-11

申请号：US12269941

申请日：2008-11-13

Applicant: Dong Liu ,  Yat Sun Or ,  Zhe Wang

Inventor： Dong Liu ,  Yat Sun Or ,  Zhe Wang

IPC: A61K31/4709 ,  C07D245/02 ,  C07D215/00 ,  C07D471/12 ,  A61K31/4375

CPC classification number: C07D471/04 ,  C07D225/04 ,  C07D245/04 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12

Abstract: The present invention discloses compounds of formula I, II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. More specifically, the invention relates to oxime compounds containing a carbocyclic P2 unit. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式I，II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 更具体地，本发明涉及含有碳环P2单元的肟化合物。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US07517859B2

公开(公告)日：2009-04-14

申请号：US11416739

申请日：2006-05-03

Applicant: Yonghua Gai ,  Datong Tang ,  Ying Sun ,  Zhigang Chen ,  Yat Sun Or ,  Zhe Wang

Inventor： Yonghua Gai ,  Datong Tang ,  Ying Sun ,  Zhigang Chen ,  Yat Sun Or ,  Zhe Wang

IPC: A61K31/70 ,  C07H17/08

CPC classification number: C07H17/08

Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

Abstract translation: 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。

公开(公告)号：US20090072983A1

公开(公告)日：2009-03-19

申请号：US11901260

申请日：2007-09-14

Applicant: Wing Ling Cheng ,  Zhe Wang ,  Huai Gang Jiang ,  Lin Guo Wang

Inventor： Wing Ling Cheng ,  Zhe Wang ,  Huai Gang Jiang ,  Lin Guo Wang

IPC: G08B21/18

CPC classification number: G01R31/40 ,  G01R31/028 ,  G01R31/343

Abstract: A power converter including a processor, at least one component whose health in the power converter will degrade over time, and at least one alarm is disclosed. The processor is configured for monitoring the health of the component over time, and for activating the alarm when the monitored health of the component reaches a threshold level.

Abstract translation: 一种功率转换器，包括处理器，至少一个其功率转换器的健康状况随时间而降低的部件，以及至少一个报警器。 处理器配置为随时间监视组件的运行状况，并在组件的监视运行状况达到阈值级别时激活报警。

公开(公告)号：US20090035271A1

公开(公告)日：2009-02-05

申请号：US11832240

申请日：2007-08-01

Applicant: Ying Sun ,  Dong Liu ,  Yat Sun Or ,  Zhe Wang

Inventor： Ying Sun ,  Dong Liu ,  Yat Sun Or ,  Zhe Wang

IPC: A61K31/41 ,  A61K31/407 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/21 ,  A61P31/12 ,  C07D245/04

CPC classification number: A61K31/01 ,  A61K31/407 ,  A61K31/41 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/21 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

公开(公告)号：US20090035267A1

公开(公告)日：2009-02-05

申请号：US11831474

申请日：2007-07-31

Applicant: Joel D. Moore ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

Inventor： Joel D. Moore ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

IPC: A61K31/50 ,  A61K38/21 ,  A61P43/00 ,  C07D237/30 ,  C07D401/00

CPC classification number: C07K5/0808 ,  A61K38/00

Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

Abstract translation: 本发明涉及可抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20080292587A1

公开(公告)日：2008-11-27

申请号：US12108659

申请日：2008-04-24

Applicant: Ying Sun ,  Yat Sun Or ,  Zhe Wang

Inventor： Ying Sun ,  Yat Sun Or ,  Zhe Wang

IPC: A61K38/05 ,  C07D207/12 ,  C07D409/12 ,  A61P31/12 ,  A61K38/21 ,  C07D405/12

CPC classification number: C07K5/0202 ,  A61K38/21 ,  C07K5/06165 ,  A61K2300/00

Abstract: The present invention discloses compounds of formulae I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式I化合物或其药学上可接受的盐，酯或前体药物：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20080286233A1

公开(公告)日：2008-11-20

申请号：US12108639

申请日：2008-04-24

Applicant: Ying Sun ,  Yat Sun Or ,  Zhe Wang

Inventor： Ying Sun ,  Yat Sun Or ,  Zhe Wang

IPC: A61K38/21 ,  C07D487/04 ,  A61P31/12 ,  A61K38/05

CPC classification number: C07D487/04 ,  A61K31/551 ,  A61K38/05 ,  A61K38/21 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20080274080A1

公开(公告)日：2008-11-06

申请号：US12108643

申请日：2008-04-24

Applicant: Yat Sun Or ,  Deqiang Niu ,  Zhe Wang

Inventor： Yat Sun Or ,  Deqiang Niu ,  Zhe Wang

IPC: A61K31/407 ,  C07D487/04 ,  A61K31/498 ,  A61K38/21 ,  A61K31/7056 ,  A61P31/12 ,  A61K31/4709

CPC classification number: C07D487/04

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20080267917A1

公开(公告)日：2008-10-30

申请号：US11740502

申请日：2007-04-26

Applicant: Deqiang Niu ,  Joel D. Moore ,  Dong Liu ,  Ying Sun ,  Yat Sun Or ,  Zhe Wang

Inventor： Deqiang Niu ,  Joel D. Moore ,  Dong Liu ,  Ying Sun ,  Yat Sun Or ,  Zhe Wang

IPC: A61K38/12 ,  A61K38/21 ,  C07K5/08 ,  A61P31/12 ,  C07K5/12 ,  A61K38/06

CPC classification number: C07K5/0812 ,  A61K38/21 ,  C07K5/0802 ,  C07K5/0808 ,  A61K2300/00

Abstract: The present invention relates to functionalized amides of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明涉及式I或式II的官能化酰胺，其包括抑制丝氨酸蛋白酶活性的药学上可接受的盐，酯或前药，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。